Unregistered Sales of Equity Securities. The Information set forth under

Other Events. On October 30, 2026, Repligen Corporation (the “Company”) issued a press release announcing the entry into privately negotiated exchange and/or subscription agreements (the “Exchange/Subscription Agreements”) with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and certain new investors, pursuant to which the Company will issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “New Notes”). Appro…

Results of Operations and Financial Condition. On October 27, 2026, Repligen Corporation announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…

At the effective time of the First Merger (the “First Merger Effective Time”), each share of BioLife’s common stock, par value $0.001 per share (“BioLife Common Stock”), issued and outstanding immediately prior to the First Merger Effective Time (other than (i) any shares that were held by BioLife in treasury or owned by Repligen, Merger Sub 1 or Merger Sub 2 and (ii) shares with respect to which appraisal rights were properly exercised and perfected, and were not withdrawn, in accordance wit…

Director — Karen A. Dawes: The filing discloses the planned retirement of a long-serving director after over twenty years, which is an orderly succession rather than a sudden loss of a senior executive.

Other Events. As previously disclosed, on July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1”), Bravo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Repligen (“Merger Sub 2”), and BioLife Solutions, Inc., a Delaware corporation (“BioLife”), pursuant to w…

Results of Operations and Financial Condition. On July 28, 2026, Repligen Corporation announced its financial results for the second quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Results of Operations and Financial Condition. On July 22, 2026, Repligen announced certain preliminary financial results for the second quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and the presentation accompanying such release and the conference call and webcast described below is attached as Exhibit 99.2 to this Current Report on Form 8-K. The information contained in

Entry into a Material Definitive Agreement. Merger Agreement On July 21, 2026, Repligen Corporation, a Delaware corporation (“Repligen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Repligen, Bravo Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Repligen (“Merger Sub 1”), Bravo Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Repligen (“Merger Sub 2”), and BioLife Solutions, Inc., a Delawar…

Results of Operations and Financial Condition. On May 5, 2026, Repligen Corporation announced its financial results for the first quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Results of Operations and Financial Condition. On February 24, 2026, Repligen Corporation announced its financial results for the fourth quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…

Chair of the Board — Tony J. Hunt: The filing announces the planned retirement of the Executive Chair and the election of a named successor, representing an orderly succession rather than a sudden loss of leadership.

Results of Operations and Financial Condition. On October 28, 2025, Repligen Corporation announced its financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…

Chief Accounting Officer — Violetta Hughes: The company hired an external executive to fill a new Chief Accounting Officer role to strengthen financial infrastructure, while the incumbent CFO retained his position with a shifted focus.

Results of Operations and Financial Condition. On July 29, 2025, Repligen Corporation announced its financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Results of Operations and Financial Condition. On April 29, 2025, Repligen Corporation announced its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…

Results of Operations and Financial Condition. On February 20, 2025, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E…

adjusted product revenue; adjusted royalty and other revenue; adjusted total revenue; adjusted cost of goods sold; adjusted R&D expense; adjusted SG&A expense; adjusted income from operations; adjusted investment income; adjusted interest expense; adjusted other income; adjusted pre-tax income; adjusted income tax provision; adjusted net income; adjusted earnings per share; and adjusted weighted average shares outstanding. The Company’s non-GAAP financial results and/or non-GAAP guidance excl…

Results of Operations and Financial Condition. On November 12, 2024, Repligen Corporation (the “Company”) announced its financial results for the third quarter ended September 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. (a) On September 12, 2024, the Audit Committee of the Board of Directors of Repligen Corporation (the “Company”), based on the recommendation of the Company’s management and after discussion with the Company’s independent registered public accounting firm, Ernst & Young LLP (“EY”), concluded that the timing of recognition of product revenue arising from a specific COVID-related cancel…

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

by reference. The Supplement Slides will be accessible through the Investors section of the Company’s website at https://www.repligen.com/ . The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing un…

Results of Operations and Financial Condition. On July 30, 2024, Repligen Corporation announced its financial results for the second quarter end June 30, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Other Information. On July 9, 2024, Repligen Corporation (the “ Company ”) discovered that an unauthorized third party had accessed certain files on the Company’s information systems. Upon this discovery, the Company immediately activated response procedures to investigate, contain, and remediate the incident and also notified law enforcement, in accordance with the Company’s established protocols. The Company has engaged external cybersecurity experts to assist with the investigation and oth…

CEO — Tony J. Hunt: The CEO is transitioning to Executive Chair with a named internal successor, indicating an orderly succession rather than a sudden loss of leadership.